ARS Pharmaceuticals, Inc.

SPRY · NASDAQ
Analyze with AI
12/31/2024
12/31/2023
12/31/2022
12/31/2021
Assets
Cash & Equivalents$50,817$70,971$210,518$60,063
Short-Term Investments$263,205$157,389$63,863$0
Receivables$9,162$795$0$1
Inventory$5,212$0$0$0
Other Curr. Assets$5,899$2,408$3,319$666
Total Curr. Assets$334,295$231,563$277,700$60,730
Property Plant & Equip (Net)$1,066$824$774$693
Goodwill$0$0$0$0
Intangibles$7,685$0$0$0
Long-Term Investments$0$0$0$0
Tax Assets$0$0$0$0
Other NC Assets$8,107$801$2,961$23
Total NC Assets$16,858$1,625$3,735$716
Other Assets$0$0$0$0
Total Assets$351,153$233,188$281,435$61,446
Liabilities
Payables$9,870$759$1,659$1,786
Short-Term Debt$42$237$230$3,623
Tax Payable$0$4$0$0
Deferred Revenue$557$0$0$1,457
Other Curr. Liab.$12,971$1,391$3,555$1,321
Total Curr. Liab.$23,440$2,391$5,444$8,187
LT Debt$0$37$251$5,410
Deferred Rev, NC$1,532$0$0$2,996
Deferred Tax Liab, NC$0$0$0$0
Other NC Liab.$69,383$0$2,854$76,122
Total NC Liab.$70,915$37$3,105$84,528
Other Liabilities$0$0$0$0
Cap. Leases$42$37$481$624
Total Liabilities$94,355$2,428$8,549$92,715
Equity
Pref Stock$0$0$0$0
Common Stock$10$10$9$3
Retained Earnings-$123,305-$131,303-$76,938-$42,256
AOCI$220$49$407$0
Other Equity$379,873$362,004$349,408$10,984
Total Equity$256,798$230,760$272,886-$31,269
Supplemental Information
Minority Interest$0$0$0$0
Total Liab. & Tot. Equity$351,153$233,188$281,435$61,446
Net Debt-$50,775-$70,697-$210,037-$51,030